70. A PHASE 1–2 CLINICAL TRIAL OF EO1001, A NOVEL IRREVERSIBLE pan-ErbB INHIBITOR WITH PROMISING BRAIN PENETRATION

CNS metastasis has become a prominent driver of morbidity and mortality in recent years as new targeted therapies have improved systemic outcomes. Mutations in the ErbB family of kinases are known oncodrivers in many of these cancers. ErbB family member “crosstalk” is associated with rapid developme...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neurooncol Adv
Päätekijät: Wheeler, Helen, Bacha, Jeffrey, Kanekal, Sarath, Pedersen, Harry, Sankar, Neil, Wang, Shen, Nesbit, Ian, Skoff, Kathy, Brown, Dennis
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Supplement Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7401413/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa073.057
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia